Skip to main content
. Author manuscript; available in PMC: 2018 Oct 25.
Published in final edited form as: Biol Blood Marrow Transplant. 2016 Apr 4;22(7):1218–1226. doi: 10.1016/j.bbmt.2016.03.027

Figure 2:

Figure 2:

Relapse-free (A) and overall survival (B) by post-remission therapy in first complete remission. Relapse free survival at 3-years was 18% with chemotherapy and 46% with HSCT as post-remission therapy in CR1. Overall survival was also different between treatment groups; 24% vs. 54% with chemotherapy and HSCT.